NeuroMetrix Stock Price, News & Analysis (NASDAQ:NURO) $3.72 +0.02 (+0.54%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$3.66▼$3.8850-Day Range$0.47▼$5.7352-Week Range$3.60▼$17.44Volume65,538 shsAverage Volume10,793 shsMarket Capitalization$4.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media About NeuroMetrix Stock (NASDAQ:NURO)NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Read More NURO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NURO Stock News HeadlinesDecember 5, 2023 | finance.yahoo.comNeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)December 1, 2023 | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.comDecember 6, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. November 30, 2023 | msn.comOPEN, AMPE and NURO are among pre market gainersNovember 20, 2023 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces One-for-Eight Reverse Stock SplitNovember 20, 2023 | finance.yahoo.comNeuroMetrix Announces One-for-Eight Reverse Stock SplitOctober 30, 2023 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023October 28, 2023 | finance.yahoo.comNeuroMetrix, Inc. (NASDAQ:NURO) Q3 2023 Earnings Call TranscriptDecember 6, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 26, 2023 | msn.comNeuroMetrix reports Q3 resultsOctober 26, 2023 | finance.yahoo.comNeuroMetrix Reports Q3 2023 Business HighlightsOctober 23, 2023 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference CallOctober 2, 2023 | finance.yahoo.comNeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with FibromyalgiaSeptember 28, 2023 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023August 30, 2023 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023August 28, 2023 | finance.yahoo.comIs NeuroMetrix (NURO) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapJuly 27, 2023 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Q2 2023 Business HighlightsJuly 27, 2023 | finance.yahoo.comNeuroMetrix Reports Q2 2023 Business HighlightsJuly 20, 2023 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference CallJuly 11, 2023 | finance.yahoo.comNeuroMetrix Announces Sales Force Expansion for Quell FibromyalgiaJune 28, 2023 | finance.yahoo.comRecent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes PatientsJune 7, 2023 | finance.yahoo.comDiabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical StudyMay 31, 2023 | finance.yahoo.comQuell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)May 16, 2023 | bizjournals.comAutonomous delivery vehicle startup Nuro is cutting staff and production to focus on R&DMay 3, 2023 | finance.yahoo.comNeuroMetrix Reports Q1 2023 Financial ResultsApril 28, 2023 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference CallMarch 21, 2023 | finance.yahoo.comNeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual MeetingSee More Headlines Receive NURO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/26/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NURO CUSIPN/A CIK1289850 Webwww.neurometrix.com Phone(781) 890-9989Fax302-636-5454Employees27Year Founded1996Profitability EPS (Most Recent Fiscal Year)($5.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,420,000.00 Net Margins-86.64% Pretax Margin-86.64% Return on Equity-25.71% Return on Assets-24.14% Debt Debt-to-Equity RatioN/A Current Ratio16.43 Quick Ratio15.11 Sales & Book Value Annual Sales$6.43 million Price / Sales0.62 Cash FlowN/A Price / Cash FlowN/A Book Value$24.09 per share Price / Book0.15Miscellaneous Outstanding Shares1,074,000Free Float993,000Market Cap$3.98 million OptionableNot Optionable Beta2.25 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Shai N. Gozani M.D. (Age 58)Ph.D., Founder, Chairman, CEO, President & Secretary Comp: $437.82kMr. Thomas T. Higgins (Age 71)Senior VP, CFO & Treasurer Comp: $342.87kDr. Xuan Kong Ph.D.Chief Data ScientistMs. Susan M. Bell R.N.Senior Vice President of Population Health & Value Based CareKey CompetitorsINVO BioscienceNASDAQ:INVOBluejay DiagnosticsNASDAQ:BJDXAvingerNASDAQ:AVGRGBSNYSE:GBSQuoin PharmaceuticalsNASDAQ:QNRXView All Competitors NURO Stock Analysis - Frequently Asked Questions How have NURO shares performed in 2023? NeuroMetrix's stock was trading at $11.92 on January 1st, 2023. Since then, NURO shares have decreased by 68.9% and is now trading at $3.71. View the best growth stocks for 2023 here. Are investors shorting NeuroMetrix? NeuroMetrix saw a drop in short interest in November. As of November 15th, there was short interest totaling 4,600 shares, a drop of 84.4% from the October 31st total of 29,400 shares. Based on an average trading volume of 6,500 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.4% of the company's shares are sold short. View NeuroMetrix's Short Interest. When is NeuroMetrix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our NURO earnings forecast. How were NeuroMetrix's earnings last quarter? NeuroMetrix, Inc. (NASDAQ:NURO) issued its earnings results on Thursday, October, 26th. The medical device company reported ($1.68) earnings per share for the quarter. The medical device company had revenue of $1.20 million for the quarter. NeuroMetrix had a negative net margin of 86.64% and a negative trailing twelve-month return on equity of 25.71%. When did NeuroMetrix's stock split? NeuroMetrix shares reverse split on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What is Shai N. Gozani's approval rating as NeuroMetrix's CEO? 10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeuroMetrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT). How do I buy shares of NeuroMetrix? Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NURO) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.